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Abstract
Purpose To report healthcare resource use and associated costs in controlled versus uncontrolled carcinoid syndrome (CS) 
in patients with neuroendocrine tumours.
Methods A cross-sectional, non-interventional multicentre study was conducted with retrospective data analysis. Resource 
use was compared between two patient groups: those with controlled CS (> 12 months with no uncontrolled CS episodes) 
and uncontrolled CS (< 12 months since last uncontrolled episode). Patients were matched for age, sex, and origin and grade 
of tumour. When no matching patients were available, data from deceased patients were used. Information on healthcare 
resource use came from review of medical records, patient history and physician reports. Working capacity was assessed 
using the Work Productivity and Activity Impairment General Health questionnaire.
Results Twenty-six university hospitals in Spain participated, between July 2017 and April 2018. 137 patients were enrolled; 
104 were analysed (2 groups of 52). Patients with uncontrolled CS had 10 times more emergency department (ED) visits 
(mean 1.0 vs 0.10 visits; P = 0.0167), were more likely to have a hospital admission (40.4% vs 19.2%; P = 0.0116) and had 
longer hospital stays (mean 7.87 vs 2.10 days; P = 0.0178) than those with controlled CS. This corresponded to higher annual 
hospitalisation costs (mean €5511.59 vs €1457.22; P = 0.028) and ED costs (€161.25 vs €14.85; P = 0.0236). The mean 
annual total healthcare costs were 60.0% higher in patients with uncontrolled than controlled CS (P = NS).
Conclusion This study quantifies higher health resource use, and higher hospitalisation and ED costs in patients with uncon-
trolled CS. Better control of CS may result 3in lower medical costs.
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Introduction
Neuroendocrine tumours (NETs) are a diverse group of 
tumours derived from neural ridge cells, endocrine glands, 
islets or cells, which share the propensity to secrete active 
hormones such as serotonin [1]. Although they are rela-
tively rare, with an incidence of around 6.98/100,000/year 
and accounting for 0.5% of all newly diagnosed malig-
nancies [2], their incidence has markedly increased over 
the past 15 years [3, 4]. While this increased incidence 
may be due to improved detection [3], diagnosis remains 
complex. This is in part due to the nonspecific and often 
late-presenting symptoms: many patients attend several 
specialists and undergo multiple investigations before a 
definitive diagnosis is made [1]. Diagnosis at a late stage 
also reduces the likelihood of being able to perform a 
complete surgical resection [5], and advanced NETs are 
frequently managed as chronic conditions, with long-term 
and often multiple treatments required [6].
Carcinoid syndrome (CS) occurs in around 10% of 
patients with NETs [7]. Its incidence varies with tumour 
type [8], increasing with tumour bulk and disease severity, 
such that it occurs in up to 30% of patients with well-dif-
ferentiated tumours [9]. A recent large, population-based 
study found CS was present in up to 19% of patients with 
NETs [10]. The most common symptoms of CS are diar-
rhoea, flushing, and dyspnoea (bronchospasm), which, 
due to disease progression or resistance to somatostatin 
analogues (SSAs), can require treatment escalation and 
modification. With disease progression, mesenteric or ret-
roperitoneal fibrosis may occur, as well as carcinoid heart 
disease. Occasionally, following a trigger such as general 
anaesthetic, a severe and life-threatening carcinoid crisis 
may occur, with massive uncontrolled release of amines, 
resulting in arrhythmias and cardiovascular instability 
[11].
The symptoms of CS are thought to be mainly due to 
serotonin, although histamine, kallikrein, prostaglandins, 
and tachykinins are likely to play a role. SSAs inhibit the 
secretion of serotonin and other neuropeptides [12]. Cur-
rent guidelines recommend SSAs as standard therapy in 
functional NETs of any origin [13], and they (octreotide 
and lanreotide) are an effective treatment in 70–90% of 
patients with CS [7, 13–16].
NETs and CS adversely impact quality of life, affecting 
physical and mental health (depression, anxiety), social 
aspects, and ability to work [1, 17–19]. Some studies in 
recent years have assessed the economic effects of NETs, 
CS, or prevalent CS symptoms, mainly in US popula-
tions [20–22]. One study looked at the use of healthcare 
resources and associated costs in a European setting [23]. 
Given this scarcity of data from a European population, 
we sought to quantify the resource use and the economic 
implications of uncontrolled CS at a national level within 
Spain. Taking into account the profound effect of CS on 
quality of life, and its chronic progressive nature, we 
hypothesised that patients with uncontrolled CS would 
have higher use of healthcare resources and consequently 




This was a non-interventional, cross-sectional, observa-
tional, multicentre study with retrospective data analysis, 
conducted in outpatient endocrinology and medical oncol-
ogy departments.
Eligible patients were ≥ 18 years old with metastatic 
grade 1–2 NETs and CS treated with SSAs. Patients were 
categorised as having uncontrolled or controlled CS based 
on the presence or absence of uncontrolled episodes within 
the previous 12 months. An uncontrolled CS episode was 
defined as at least one of the following: > 4 episodes of diar-
rhoea per day for > 1 month, > 1 month of flushing (≥ 1 
flushing episode/week for > 1 month), doses of SSAs higher 
than the standard doses (> 120 mg/4 weeks of lanreotide or 
> 30 mg/4 weeks of octreotide), or worsening of carcinoid 
heart disease or mesenteric fibrosis. The study excluded 
patients with other malignant disease, or with other severe 
diseases that could interfere with assessment of CS, such as 
right cardiomyopathy or diarrhoea of a different aetiology, 
those participating in another clinical study, and those who 
could not read or understand the study questionnaires.
The study aimed to enrol 130 patients in total, divided 
into the controlled CS and uncontrolled CS groups. Patients 
in these two groups were matched for tumour origin and 
grade. Where possible, they were also matched for evidence 
of stability/progression and length of treatment (< 1 year; 
1–2 years; or > 2 years). If insufficient matched patients 
were available, then deceased ones were included, provided 
their medical records contained the minimum information 
required.
The study consisted of a single visit that coincided with 
an already-scheduled medical appointment, during which 
sociodemographic and clinical variables were collected 
directly from the patients or from their medical records. The 
physician provided information on the clinical status of the 
disease and the patients completed a questionnaire on their 
working capacity. Data were collected from 6 to 12 months 
before the study visit for patients with controlled CS, and 
from 3 months before and 6 to 12 months after the last CS 
episode for patients with uncontrolled CS. The analysis was 
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adjusted according to the relative time at which the informa-
tion was collected: from 6 to 12 months in the uncontrolled 
vs from 9 to 15 months in the controlled CS group.
Objectives and variables
The primary objective was to determine the use of healthcare 
resources and their associated costs and the effects on capac-
ity to work in patients with controlled and uncontrolled CS 
and grade 1–2 metastatic NETs receiving SSAs. Direct costs 
comprised number of hospitalisations, length of stay, visits 
to emergency departments (ED), outpatient visits including 
primary care, investigations performed, treatment received 
for NET and CS, and surgical and other procedures related 
to NET or CS.
Effects on capacity to work were based on the responses 
to the Work Productivity and Activity Impairment General 
Health (WPAI-GH) questionnaire [24], which assesses the 
occupational impact of a disease over the past 7 days. Only 
those patients in employment at the time of the study visit 
completed this questionnaire. From the responses, we cal-
culated absenteeism (number of hours lost/total number of 
hours the individual should have worked); presenteeism, 
defined as deterioration in the capacity to work, rated on a 
Likert-type scale from 0 (no deterioration) to 10 (completely 
unable to perform tasks); overall work impairment and activ-
ity impairment due to health, all expressed as percentages 
[25]. In addition, patients with uncontrolled CS answered 
ad hoc questions on occupational absenteeism at the time of 
the last carcinoid episode, and deceased patients’ medical 
records were reviewed to answer as many as possible of the 
ad hoc questions. Supplementary materials S1 and S2 con-
tain the WPAI-GH questionnaire and the ad hoc questions.
The secondary objective was to describe the clinical 
characteristics and management of the patient groups. The 
following variables were collected: NET diagnostic proce-
dure, time since NET diagnosis, origin and grade of tumour, 
treatment prescribed following NET diagnosis, time from 
diagnosis to first intervention, NET treatment, CS treat-
ment, current symptoms, comorbidities, New York Heart 
Association (NYHA) classification, pro-brain natriuretic 
peptide (proBNP) levels, chromogranin A and 5-hydrox-
yindoleacetic acid (5-HIAA) levels, latest echocardiogram 
result, Eastern Cooperative Oncology Group (ECOG) per-
formance status, patient-perceived health status and physi-
cian-reported disease status. In patients with uncontrolled 
CS, the time since the last carcinoid episode and the duration 
of the episode were also described, and the number and per-
centage of patients with valvular heart disease were calcu-
lated. Physicians and patients were also asked to categorise 
their (patients’) health status as good, neither good nor bad, 
or bad, to determine whether their opinions correlated.
Ethics
This non-interventional study was approved by the Ethics 
Committee of Hospital Universitari de Bellvitge, Barcelona 
(27 April 2017), and classified as a post-approval study by 
the Spanish Agency for Medicines and Medical Devices 
(AEMPS; 16 February 2017). The study followed the Inter-
national Society for Pharmacoepidemiology Guidelines on 
Good Pharmacoepidemiological Practice [26]. Prior to any 
data collection, living participants received a full explana-
tion and provided written informed consent. In the case of 
deceased participants, following ethics committee review, 
consent from living relatives was not required.
Statistical analysis
Unmatched patients were excluded from all analyses. Use 
of healthcare resources (hospitalisation, hospital depart-
ment and length of stay, visits to ED, outpatient and pri-
mary care visits, tests and medical interventions performed) 
were analysed using descriptive statistics. The two groups 
(controlled vs uncontrolled CS) were then compared using 
the Cochran–Mantel–Haenszel test for resource consump-
tion (any use) and paired t test for the number of times the 
resource was used. Direct costs were calculated per patient 
and per year, based on local costs per unit. Data on costs 
were obtained from national data sources [27, 28], accord-
ing to the perspective of the Spanish national health system. 
Direct costs between groups were compared using the paired 
t test and the Wilcoxon test.
The secondary endpoints of clinical characteristics and 
management were analysed using descriptive analysis and 
compared between groups using a paired t test for continu-
ous variables and the Cochran–Mantel–Haenszel test or con-
ditional logistic regression for categorical variables.
Given the lack of existing comparative data on patients 
with controlled vs uncontrolled CS, the study sample size 
was calculated using a continuous variable. To detect dif-
ferences ≥ 0.35 standard deviation (moderate differences) 
between patients with controlled or uncontrolled CS (paired 
data) with a significance level of 0.05 and a statistical power 
of 0.8, a sample size of ≥ 65 patients per group was deter-
mined. All data were collected from real clinical practice; 
if an assessment was not performed as part of routine care, 
missing data were not replaced.
Results
Participants
Twenty-six university hospitals in Spain participated, 
between July 2017 and April 2018. One hundred and 
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thirty-seven patients were enrolled; 33 were excluded (no 
matching patient [24], not treated with an SSA [6], or taking 
part in another study [3]), leaving 104 for the analysis, 52 in 
each group. The uncontrolled CS group included 10 (19.2%) 
deceased patients. Overall, the mean age was 64.3 years and 
53.8% were men. The sociodemographic and clinical char-
acteristics of the two groups are shown in Table 1. Clinical 
and treatment characteristics are reported below as second-
ary outcomes.
Primary objective: healthcare resource use 
and direct associated costs
Hospitalisation, ED visits and outpatient clinics
There were large and statistically significant differences 
in acute medical care between the two groups (Table 2). 
In the uncontrolled CS group, 40.4% of patients required 
hospital admission vs 19.2% of the controlled CS group 
(P = 0.0116), and the duration of hospital stay was longer 
in the uncontrolled (mean 7.9 days) than in the controlled 
(mean 2.1 days) CS group (P = 0.0178). More patients in 
the uncontrolled (32.7%) than in the controlled CS group 
(5.8%) visited the ED (P = 0.0010), and the mean number of 
ED visits was ten times higher in the uncontrolled CS group 
than in the controlled CS group (1.0 vs 0.10, respectively; 
P = 0.0167).
There were no statistically significant differences in total 
outpatient attendances between the two groups: 61.5% of 
the uncontrolled CS group and 63.5% of the controlled CS 
group had at least one visit, and the mean number of visits 
was 6.2 overall. Table 2 includes breakdown by department 
and specialty for ED and outpatient attendance.
This direct healthcare usage translated to a statistically 
significant difference in the annual cost of hospitalisation for 
uncontrolled vs controlled CS: mean €5511.59 vs €1457.22, 
respectively (P = 0.0280) (Table 2). Mean ED costs were 
also significantly higher in uncontrolled than controlled CS: 
€161.25 vs €14.85 per patient year (P = 0.0236). Total out-
patient clinic costs were higher in patients with uncontrolled 
vs controlled CS, without reaching statistical significance. 
Visits to the medical oncologist constituted the highest out-
patient costs (P = NS); this was followed by endocrinology 
visits, which were more frequent in patients with uncon-
trolled CS (P = 0.0350).
Investigations: imaging, laboratory tests and biopsies
Overall, 97.1% of patients had undergone at least one imag-
ing study (morphological or functional) during the period 
assessed: mean (SD) 4.2 (2.8) tests per patient. The most-
used techniques were high-resolution computed tomography 
(HRCT) (in 90.4%), scintigraphy with octreotide (59.6%), 
magnetic resonance imaging (28.8%), and abdominal 
ultrasound (20.2%). There were no significant differences 
between the two groups for any of these investigations.
Abdominal X-ray was performed in 5 patients with 
uncontrolled CS and in 0 patients with controlled CS 
(P = 0.0253). Overall, 9.6% of patients underwent endos-
copy, but there were no significant differences between the 
two groups. Table 3 shows the number of tests performed 
per group.
Overall, 95.2% of patients had at least one laboratory test 
(e.g. blood or urine). There was a significant difference in the 
mean number of urine tests performed: 2.27 in the uncon-
trolled vs 1.44 in the controlled CS group (P = 0.0084), but 
not in the mean number of blood tests.
There were no significant differences between groups in 
the number of patients undergoing biopsy or the number 
of biopsies performed. Immunohistochemistry staining 
Table 1  Patient demographics
SD standard deviation, min minimum, max maximum
a Other: students, retired, homemaker
b Data not available in ten patients (not recorded in notes)
Variable Uncontrolled CS Controlled CS
Age in years, mean (SD); min–max 63.75 (12.17); 37–87 64.88 (12.04); 38–92
Sex, female, n (%) 22 (42.3%) 26 (50.0%)
Employment status, n (%) n =  42b n = 52
 Employed 6 (14.3%) 10 (19.2%)
 Unemployed 6 (14.3%) 14 (26.9%)
  Othera 30 (71.4%) 28 (53.8%)
Education level n = 52 n = 52
 No formal education 4 (7.7%) 2 (3.8%)
 Primary 20 (38.5%) 20 (38.5%)
 Secondary 15 (28.8%) 18 (34.6%)
 University or postgraduate studies 13 (25.0%) 12 (23.1%)
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(which included chromogranin, synaptophysin, enolase, 
insulin, CD56, CDX2, KI67, PAX8, and TTF-1) was also 
not significantly different.
The annual cost of all investigations was significantly 
higher in the uncontrolled CS group than in the controlled 
CS  one: mean €3606 vs €2310 (P = 0.0486). Table  3 
shows investigation costs by category, and supplementary 
Table 2  Hospital admissions, emergency department visits, and outpatient clinic visits during the study period and their corresponding annual 
costs in Euros
ED emergency department, GI gastrointestinal, ICU intensive care unit, SD standard deviation
*Statistically significant (P < 0.05)
a Adjusted according to the relative time at which the information was collected: from 6 to 12 months in the uncontrolled vs from 9 to 15 months 
in the controlled CS group
b Mantel–Haenszel Chi-square
c Paired t test





P value Uncontrolled CS Controlled CS P value
Any hospitalisation, n (%) 21 (40.4%) 10 (19.2%) 0.0116*b 5511.59 (10,166.14) 1457.22 (3346.59) 0.0280*c
No. of hospitalisations, mean (SD) 0.62 (0.97) 0.25 (0.59) 0.0024*c
Length of stay, days, mean (SD) 7.87 (13.66) 2.10 (4.90) 0.0178*c
Department admitted to, n (%)
 General and GI surgery 5 (9.6%) 5 (9.6%)
 Endocrinology 4 (7.7%) 0
 Internal medicine 2 (3.8%) 0
 Nuclear medicine 1 (1.9%) 1 (1.9%)
 Medical oncology 13 (25.0%) 3 (5.8%)
 Palliative care 1 (1.9%) 0
 ICU 1 (1.9%) 0
 GI 0 1 (1.9%)
Any ED visit, n (%) 17 (32.7%) 3 (5.8%) 0.0010*b 161.25 (333.48) 14.85 (63.13) 0.0236*c
No. of ED visits, mean (SD) 1.0 (2.05) 0.10 (0.41) 0.0167*c
Any outpatient visit, n (%) 32 (61.5%) 33 (63.5%) 0.8273b 633.34 (838.32) 510.03 (661.29) 0.2322c
No. of outpatient visits (all specialties), 
mean (SD)
6.48 (8.41) 5.87 (7.54) 0.1731c
No. of outpatient visits, by specialty, mean (SD)
 Primary care 0.37 (2.11) 0.58 (2.86)
 Cardiology 0.38 (0.75) 0.13 (0.34)
 General surgery 0.44 (2.04) 0.79 (2.27)
 Dermatology 0.04 (0.28) 0.00 (0.00)
 Endocrinology 1.10 (2.56) 0.85 (1.66)
 Gynaecology 0 (0.00) 0 (0.00)
 Internal medicine 0 (0.00) 0.02 (0.14)
 Nuclear medicine 0.15 (0.64) 0.23 (0.85)
 Pneumonology 0.10 (0.41) 0 (0.00)
 Medical oncology 3.85 (5.85) 3.15 (5.15)
 Interventional radiology 0.02 (0.14) 0.00 (0.00)
 Nephrology 0 (0.00) 0.02 (0.14)
 Neurology 0 (0.00) 0.04 (0.28)
 Ophthalmology 0 (0.00) 0.04 (0.19)
 Radiation oncology 0.04 (0.28) 0.02 (0.14)
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material S3 shows further breakdown of usage within each 
category.
Treatments
Pharmacological treatment for  CS The mean total annual 
cost of pharmacological treatment for CS was higher in the 
uncontrolled CS (€25,924.80) than in the  controlled CS 
group (€18,219.15) but the difference did not reach statis-
tical significance (P = 0.2228) (Table  4). Pharmacological 
treatment represented 80.2% of patients with NETs’ total 
annual cost. As part of the study inclusion criteria, all par-
ticipants were receiving SSAs, and they made up 48.7% of 
the annual treatment costs. In patients with uncontrolled CS, 
SSA costs made up 37.0% of the mean total pharmacologi-
cal treatment costs, while in patients with uncontrolled CS, 
they made up 58.8%.
Interventions and  surgical procedures (related 
to  NETs) There was no difference in the  overall use of 
interventions between the two groups. Seven out of 52 
patients in each group underwent an intervention (e.g. 
chemo-/radioembolization, valve replacement or bowel 
resection). Table  4 shows the breakdown of procedures 
performed and corresponding annual costs.
Total direct costs The mean annual direct healthcare costs, 
that is, investigations plus treatments plus inpatient and 
outpatient medical care, were 60% higher in patients with 
uncontrolled CS than patients with controlled CS, though 
this difference did not reach statistical significance: mean 
(SD) €39,385.39 (€32,438.53) in patients with uncon-
trolled CS vs €24,543.53 (€19,449.49) in patients with 
controlled CS (P = 0.0535) (Table 4).
Effect on capacity to work: WPAI‑GH questionnaire 
and ad hoc questions
Of the 17 patients who were employed at the study visit, 12 
completed the WPAI-GH questionnaire. The questionnaire 
was not completed for deceased patients. There were insuf-
ficient paired cases to perform a comparison between both 
groups. Table 5 reports the WPAI-GH results by group. Of 
note, there was 32.5% absenteeism in the uncontrolled CS 
group vs 20.5% in the controlled CS group.
Forty-one patients from the uncontrolled CS group com-
pleted the ad hoc questions. These showed that at the time of 
the last carcinoid episode only two patients were in employ-
ment. Of the 39 who were not in employment, 21/39 (53.8%) 
were retired, 12/39 (31.6%) were on medical leave and 5/39 
(12.8%) were unemployed (missing data on one patient). Of 
the two patients in employment, neither had medical leave 
during their last CS episode, but one patient had had to leave 
work early (any incidence) and one had been unable to go to 
work (any incidence).
Secondary objectives: clinical characteristics 
and management
Supplementary material S4 contains the full details of 
the clinical characteristics of the patients in both groups; 
the groups were well matched. Overall, the median 
Table 3  Use of investigations by category during the study period and corresponding annual costs in Euros
Mean (SD) for all parameters. Further breakdown within categories is provided in Supplementary Table S3
CS carcinoid syndrome
*Statistically significant (P < 0.05)
a Paired t test





P value Uncontrolled CS Controlled CS P value
Morphological and func-
tional imaging
4.69 (3.27) 3.63 (2.11) 0.3273a 961.60 (931.03) 887.41 (907.57) 0.2317a
Endoscopy 0.13 (0.40) 0.08 (0.27) 0.7845a 87.96 (282.67) 49.67 (173.74) 0.8803a
Laboratory tests 16.71 (11.61) 10.85 (7.86) 0.0730a 1967.86 (1721.73) 1257.45 (1056.27) 0.1302a
Blood tests 14.44 (10.79) 9.40 (7.15) 0.1502 a – – –
Urine tests 2.27 (2.47) 1.44 (1.67) 0.0084a – – –
Biopsy 0.46 (1.24) 0.17 (0.43) 0.0744a 560.11 (1643.71) 91.73 (228.05) 0.0981a
Immunohistochemistry 0.58 (1.21) 0.50 (1.28) 0.4402a 28.48 (60.71) 23.80 (60.71) 0.4775a
Total investigations 3606.01 (3133.90) 2310.06 (1829.55) 0.0486*a
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[interquartile range (IQR)] time between NET diagnosis 
and the study visit was 4.9 (2.2–8.5) years. The most fre-
quent (73.1%) tumour origin was intestine, and 53.8% of 
NETs were grade 1. The most common site of metastases 
was the liver. NETs were most frequently diagnosed with 
morphological imaging (77.9%); HRCT in 70.2%. The 
most common tumour studies for diagnosis were chro-
mogranin A and synaptophysin; serum chromogranin A 
and urinary 5-HIAA were also used frequently (supple-
mentary material S4). The most common first therapeutic 
Table 4  Treatment usage, corresponding annual treatment costs, and total annual healthcare costs in Euros
CS carcinoid syndrome, IQR interquartile range, NET neuroendocrine tumour, na not available, max maximum, min minimum, SD standard 
deviation
















52 (100%) 52 (100%) na 10,780.83 (6470.63) 10,721.55 (5929.63) 0.9285
 Chemotherapy 3 (5.8%) 2 (3.8%) 0.6547 25.03 (105.57) 163.39 (1119.24) 0.3805
 Targeted therapy 18 (34.6%) 9 (17.3%) 0.0495* 10,710.17 
(23,236.10)
5437.10 (15,076.08) 0.2863
 Other 4 (7.7%) 3 (5.8%) 0.7055 3527.39 (14,244.52) 1897.12 (9220.04) 0.5505
CS therapies
 Antiemetics 2 (3.8%) na na 11.85 (62.50) na na
 Antidiarrheals 17 (32.7%) na na 88.54 (201.05) na na
 Antihistamines 2 (3.8%) na na 0.21 (1.18) na na
 Other 5 (9.6%) na na 780.69 (3527.40) na na
Interventions and 
surgical procedures
3548.50 (11,905.15) 2032.21 (8292.85) 0.8885
 Chemoemboliza-
tion
1 (1.9%) 1 (1.9%)
 Radioembolization 1 (1.9%) 1 (1.9%)
 Liver transplant 1 (1.9%) 0
 Partial liver resec-
tion
1 (1.9%) 3 (5.8%)
 Right hemicolec-








 Change of biliary 
prosthesis
0 1 (1.9%)




 Lutetium therapy 1 (1.9%) 0
Total annual direct costs (treatment + investigations + clinical care)
Uncontrolled CS Controlled CS P value
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intervention was surgery, in 62.5% (43.3% had partial 
resection of primary tumour); 37.5% received pharmaco-
logical treatment as their first treatment. The median time 
between diagnosis and first intervention was 18.5 days 
(IQR 0.0–57.7 days). As expected, the most commonly 
reported symptoms were diarrhoea, skin flushing, and 
abdominal pain. Only four patients in the uncontrolled 
CS group reported dyspnoea. Overall, 55.8% of patients 
had comorbidities, the most common being hypertension 
(31.7%), hyperlipidaemia (15.4%) and diabetes mellitus 
(11.5%).
Supplementary material S4 also contains the mean 
values for biochemistry markers and echocardiography 
results by group. Overall, 57.9% of patients had a normal 
echocardiogram while 28.1% had tricuspid valve disease. 
According to NYHA classification, 8.7% of patients 
with uncontrolled CS has moderate or severe (class III 
or IV) limitation of physical activity, while no patient 
in the controlled CS group had this degree of limitation 
(P = 0.0455). In total, 27.7% of the patients included in 
this study had an ECOG performance status of 0, and 
94.7% had ECOG of 0 or 1. Statistically significant dif-
ferences in ECOG were not observed between groups.
Figure 1 shows the perceived health status according to 
the physician or patient perspective for the controlled and 
uncontrolled CS groups: physician and patient opinions 
were generally in agreement.
Discussion
Our study aimed to quantify the use of resources and the 
associated costs in patients with grade 1–2 metastatic 
NETs, comparing those with controlled and uncontrolled 
CS. As a secondary objective we described the patients’ 
clinical characteristics and management. We found that 
patients with uncontrolled CS had significantly higher 
rates of acute healthcare resource use than patients with 
controlled CS: they were more likely to require hospitali-
sation, had longer duration of hospital stay, and incurred 
higher mean hospitalisation costs. In addition, patients 
with uncontrolled CS were more likely to visit the ED 
and had 10 times more ED visits, with consequent higher 
costs than patients with controlled CS.
Besides these acute care costs, costs in other areas such 
as outpatient clinic attendance, treatments, or investiga-
tions, while being higher in the uncontrolled CS group, did 
not reach statistical significance. Of the treatment costs, 
SSA costs were similar between groups (mean €10,780.83 
and €10,721.55), whereas the mean cost of targeted thera-
pies was close to double in the uncontrolled CS vs con-
trolled CS group (€10,710.17 vs €5437.10). This could 
reflect the increased use of targeted therapy (e.g. everoli-
mus) in an attempt to control symptoms, since this agent 
has been shown to improve symptoms when combined 
with SSAs [29].
Our findings of a 60.0% increase in total costs in 
patients with uncontrolled CS over a 12-month period are 
similar to those from a Swedish study by Lesén et al. [23], 
who described a close to 40% increase in total costs in those 
with uncontrolled vs controlled CS, for an 8-month period. 
Lesén et al. also found that patients with carcinoid heart 
disease incurred additional costs. We did not assess this 
cost specifically, although we did find a greater incidence of 
valvulopathy, and worse NYHA classification in the uncon-
trolled vs controlled CS group. Having more patients with 
valvulopathy in the uncontrolled CS group may be one of 
the underlying factors for the increased costs observed, due 
to additional investigations and outpatient clinic attendance. 
Carcinoid heart disease is an established complication of 
uncontrolled CS and, as such, should be considered as a 
potential cost burden within these patients. In the study by 
Lesén et al., differences were driven by SSA costs, medi-
cal interventions such as hepatic artery embolisation were 
higher, and there were no differences in hospitalisations or 
targeted therapies. This may reflect a lack of standardisation 
Table 5  Results of the WPAI-GH questionnaire
Results are reported as mean percentage (standard deviation) per 
patient
Variable Uncontrolled CS Controlled CS
Absenteeism, % 32.5 (47.2) 20.5 (36.5)
Presenteeism, % 26.7 (46.2) 22.9 (29.8)
Overall work impairment, % 28.7 (49.7) 27.6 (33.9)
Activity impairment, % 30.0 (52.0) 24.3 (32.6)
Fig. 1  Perceived health status (good, neither good nor bad, or bad) 
according to patients and their physicians. CS carcinoid syndrome, Dr 
physician’s opinion; pt patient’s opinion
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in how to manage patients with uncontrolled CS, probably 
due to lack of approved or evidence-based treatments in 
cases when SSAs alone do not control symptoms.
Regarding the effects of the disease on the capacity to 
work, it is difficult to draw clear conclusions about the 
impact of uncontrolled and controlled CS. A recent study 
by Singh et al. [1] found that 39% of patients with NETs 
(mean age, 56.8 years) were in employment, and 18% 
had a self-identified medical disability. In our study, the 
percentage of unemployed patients (21.3%) and patients 
with the employment status other (61.7%, n = 58) (includ-
ing homemakers, students, and retirees), meant only 12 
patients (11.8%) completed the WPAI-GH questionnaire. 
Based on the low percentage of employed patients who 
completed the questionnaire, it could be concluded that 
CS negatively affects the working situation of both study 
groups (controlled and uncontrolled CS), with a total 
absenteeism of 24.5% (higher in the uncontrolled CS 
group, 32.5% vs 20.5% in the controlled CS group), and a 
total presenteeism of 24% (26.7% in uncontrolled vs 22.9% 
in controlled CS group). However, the mean age of study 
participants (64.3 years) could go some way to explaining 
the large proportion with other status, as many of these 
individuals may be retired. The lack of distinction between 
different statuses in the category other could therefore be 
considered a limitation of the study. Nonetheless, the fact 
that at the time of the last carcinoid episode, only two 
patients in the uncontrolled group were actively work-
ing and 31.6% of the remaining patients were on medical 
leave also indicates a potential effect of uncontrolled CS 
on patients’ capacity to work. A more in-depth study on 
effects on capacity to work and corresponding financial 
costs would be beneficial to give a more global view of 
the costs incurred.
The study by Singh et al. also found that oncologists and 
haematologists made up 70% of outpatient clinic visits in 
patients with NETs [1]. In our study in the setting of meta-
static NETs, medical oncology was also the most-visited 
specialty, which fits with expectations. Likewise, medical 
oncology was also the most frequent specialty under which 
patients were admitted to hospital. Although we did not 
differentiate between hospitalisation due to CS or to other 
causes, there were no major differences in comorbidities 
between the two groups. Therefore, given the similar levels 
of comorbidities and the specialties the patients were treated 
under, it would be reasonable to interpret that the increased 
costs could have derived from CS.
Few European studies have looked at resource use in CS. 
In 2017, Shen et al. [20] published a US study based on 
the SEER registry and Medicare data from 6700 patients, in 
which they analysed cost patterns in elderly NET patients, 
comparing those with and without CS. They found median 
total costs of more than 1000 USD/month higher, and 
significantly higher total inpatient and outpatient costs in 
patients with CS than those without CS, even after control-
ling for clinical and demographic factors. Patients with CS 
were significantly more likely to have ED attendance and 
hospitalisation. Our study design differed in that it did not 
look specifically at older patients (although mean age was 
63.4 years) and in that we differentiated between controlled 
vs uncontrolled CS rather than the presence or absence of 
CS. Nonetheless, many of the patterns described by Shen 
et al. were reflected in our study, to a slightly more modest 
level, with a median increase in the uncontrolled CS group 
for total healthcare costs of over €7000 per year, and a mean 
increase of over €14,000.
Another US study [21], looking specifically at diarrhoea 
in CS, found that patients with diarrhoea had significantly 
higher rates of healthcare resource use than those without. 
In line with our findings, they also reported higher rates of 
hospitalisation, ED attendances, outpatient clinic visits and 
duration of hospital stay. CS-associated diarrhoea accounted 
for a 1.5-fold higher total healthcare spending, only slightly 
lower than our result of 60.0% (that is, 1.6-fold) higher 
costs in those with uncontrolled CS, which included any 
CS-related symptom (not only diarrhoea).
Huynh et al. [22], in an economic study on dose escala-
tion of SSAs, found that patients with CS symptom improve-
ment had significantly lower annual healthcare costs (14,766 
USD per patient) than patients with continued symptoms of 
flushing or diarrhoea. Their study included an analysis of 
indirect costs, including, for example, hours spent at clinic 
visits and corresponding loss of earnings, a point which we 
did not calculate in the present study, but which would be 
informative.
Some limitations to the RECOSY study should be noted. 
First, this study was cross-sectional and based on medical 
records, patient history, and physician reporting. Therefore, 
any reported outcomes are likely to be subject to recall bias, 
and parameters that were not recorded as part of routine 
clinical practice were unavailable. However, strengths of the 
study include that these findings are reflective of real clini-
cal practice, as the study was conducted in 26 public uni-
versity hospitals throughout Spain, and included data from 
primary care. This characteristic, in addition to the fact that 
the Spanish public health system is universal, increases the 
likelihood of the findings being representative of the national 
population with NETs and CS. A second limitation is that, 
due to a lack of matching patients, deceased patients’ medi-
cal records had to be used, which is suboptimal; however, 
ensuring this matching we aimed to increase the robustness 
of the analysis.
To our knowledge, RECOSY is the first study to report 
the use of resources and the associated direct and indirect 
costs for CS in Spain, and is among the few that exist for 
European countries [23, 30]. It provides detailed data on the 
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scope of the healthcare and economic burden of CS in this 
setting. Given that the incidence of NETs continues to rise 
and survival is increasing [2], the economic implications 
of NETs and CS management may proportionally increase 
further in the future. Our study should be considered along-
side previous studies on quality of life [18, 19, 31, 32] to 
ensure that medical teams are aware of the impact of CS 
on patients’ lives and the resources they require, and how 
these factors can vary according to whether or not CS is con-
trolled. It is hoped that this will be useful for those involved 
in research on this disease, and ultimately help in decision-
making for appropriate allocation of health resources.
Conclusion
Compared with patients with controlled CS, patients with 
uncontrolled CS require more ED visits, more hospital 
admissions, and longer hospital stays, resulting in higher 
acute care costs and a trend towards higher total costs.
Supplementary Information The online version contains supplemen-
tary material available at https:// doi. org/ 10. 1007/ s12094- 021- 02608-7.
Acknowledgements The authors thank all patients involved in the 
study, as well as their caregivers, care teams, and investigators.
Author contributions The study was conceived and designed by NC 
and GC. Data were collected and analysed by NC. The first draft of 
the manuscript was written by NC and GC with the assistance of a 
medical writer, and all authors commented on previous versions of 
the manuscript. All authors read and approved the final manuscript.
Funding This study was sponsored by Ipsen. Medical writing support 
was provided by Jane Marshall (freelance, Barcelona, Spain) which 
was funded by Ipsen in accordance with Good Publication Practice 
Guidelines.
Declarations 
Conflict of interest PJF: travel grants from Ipsen and consulting/advi-
sory role for Bristol, Mylan, Rovi, LeoPharma, ADACAP, all outside 
of the scope of this work; ACB: travel grants and honoraria from Ip-
sen, Roche and Novartis and consulting/advisory role for Roche, Rovi, 
LeoPharma, Pfizer, Esteve, Elsevier, Bristol, all outside of the scope 
of this work; MIDO: honoraria and/or research grants and/or advisory 
board and/or consultancy fees from ADACAP, Ipsen, Novartis, Pfizer; 
IL: honoraria and/or congress support from Bristol Myers, Novartis, 
Pfizer, Pierre Fabre, Roche; JÁD: Ipsen advisory board; NC: employee 
of IQVIA; MP, GDLC: employees of Ipsen; ACB: honoraria and/or 
advisory board from BMS, Ipsen, MSD, Novartis, Pfizer; CV, MJG: 
nothing to disclose.
Availability of data and material Where patient data can be 
anonymised, Ipsen will share all individual participant data that under-
lie the results reported in this article with qualified researchers who 
provide a valid research question. Study documents, such as the study 
protocol and clinical study report, are not always available. Proposals 
should be submitted to DataSharing@Ipsen.com and will be assessed 
by a scientific review board. Data are available beginning 6 months 
and ending 5 years after publication; after this time, only raw data 
may be available.
Ethics approval and consent to participate This non-interventional 
study was approved by the Ethics Committee of Hospital Universi-
tari de Bellvitge, Barcelona (27 April 2017), and classified as a post-
approval study by the Spanish Agency for Medicines and Medical 
Devices (AEMPS; 16 February 2017). The study followed the Inter-
national Society for Pharmacoepidemiology Guidelines on Good Phar-
macoepidemiological Practice [26]. Prior to any data collection, living 
participants received a full explanation and provided written informed 
consent. In the case of deceased participants, following ethics commit-
tee review, consent from living relatives was not required.
Informed consent Subjects signed the informed consent.
Open Access This article is licensed under a Creative Commons Attri-
bution 4.0 International License, which permits use, sharing, adapta-
tion, distribution and reproduction in any medium or format, as long 
as you give appropriate credit to the original author(s) and the source, 
provide a link to the Creative Commons licence, and indicate if changes 
were made. The images or other third party material in this article are 
included in the article’s Creative Commons licence, unless indicated 
otherwise in a credit line to the material. If material is not included in 
the article’s Creative Commons licence and your intended use is not 
permitted by statutory regulation or exceeds the permitted use, you will 
need to obtain permission directly from the copyright holder. To view a 
copy of this licence, visit http:// creat iveco mmons. org/ licen ses/ by/4. 0/.
References
 1. Singh S, Granberg D, Wolin E, et al. Patient-reported burden of 
a neuroendocrine tumor (NET) diagnosis: results from the first 
global survey of patients with NETs. J Glob Oncol. 2016;3(1):43–
53. https:// doi. org/ 10. 1200/ JGO. 2015. 002980 (Published 2016 
Jun 8).
 2. Dasari A, Shen C, Halperin D, et al. Trends in the incidence, prev-
alence, and survival outcomes in patients with neuroendocrine 
tumors in the United States. JAMA Oncol. 2017;3(10):1335–42. 
https:// doi. org/ 10. 1001/ jamao ncol. 2017. 0589.
 3. Hallet J, Law CH, Cukier M, Saskin R, Liu N, Singh S. Exploring 
the rising incidence of neuroendocrine tumors: a population-based 
analysis of epidemiology, metastatic presentation, and outcomes. 
Cancer. 2015;121(4):589–97. https:// doi. org/ 10. 1002/ cncr. 29099.
 4. Taal BG, Visser O. Epidemiology of neuroendocrine tumours. 
Neuroendocrinology. 2004;80(Suppl 1):3–7. https:// doi. org/ 10. 
1159/ 00008 0731.
 5. Oronsky B, Ma PC, Morgensztern D, Carter CA. Nothing but 
NET: a review of neuroendocrine tumors and carcinomas. Neo-
plasia. 2017;19(12):991–1002. https:// doi. org/ 10. 1016/j. neo. 2017. 
09. 002.
 6. Plöckinger U, Rindi G, Arnold R, et al. Guidelines for the diagno-
sis and treatment of neuroendocrine gastrointestinal tumours. A 
consensus statement on behalf of the European Neuroendocrine 
Tumour Society (ENETS). Neuroendocrinology. 2004;80(6):394–
424. https:// doi. org/ 10. 1159/ 00008 5237.
 7. Aluri V, Dillon JS. Biochemical testing in neuroendocrine tumors. 
Endocrinol Metab Clin N Am. 2017;46(3):669–77. https:// doi. org/ 
10. 1016/j. ecl. 2017. 04. 004.
Clinical and Translational Oncology 
1 3
 8. Rorstad O. Prognostic indicators for carcinoid neuroendocrine 
tumors of the gastrointestinal tract. J Surg Oncol. 2005;89(3):151–
60. https:// doi. org/ 10. 1002/ jso. 20179.
 9. Öberg K, Knigge U, Kwekkeboom D, Perren A, ESMO Guide-
lines Working Group. Neuroendocrine gastro-entero-pancreatic 
tumors: ESMO clinical practice guidelines for diagnosis, treat-
ment and follow-up. Ann Oncol. 2012;23(Suppl 7):vii124–30. 
https:// doi. org/ 10. 1093/ annonc/ mds295.
 10. Halperin DM, Shen C, Dasari A, et al. Frequency of carcinoid syn-
drome at neuroendocrine tumour diagnosis: a population-based 
study. Lancet Oncol. 2017;18(4):525–34. https:// doi. org/ 10. 1016/ 
S1470- 2045(17) 30110-9.
 11. Rubin de Celis Ferrari AC, Glasberg J, Riechelmann RP. Carci-
noid syndrome: update on the pathophysiology and treatment. 
Clinics (Sao Paulo). 2018;73(suppl 1):490. https:// doi. org/ 10. 
6061/ clini cs/ 2018/ e490s.
 12. Kulke MH, O’Dorisio T, Phan A, et al. Telotristat etiprate, a 
novel serotonin synthesis inhibitor, in patients with carcinoid 
syndrome and diarrhea not adequately controlled by octreotide. 
Endocr Relat Cancer. 2014;21(5):705–14. https:// doi. org/ 10. 1530/ 
ERC- 14- 0173.
 13. Pavel M, Baudin E, Couvelard A, et  al. ENETS Consensus 
Guidelines for the management of patients with liver and other 
distant metastases from neuroendocrine neoplasms of foregut, 
midgut, hindgut, and unknown primary. Neuroendocrinology. 
2012;95(2):157–76. https:// doi. org/ 10. 1159/ 00033 5597.
 14. Toumpanakis C, Caplin ME. Update on the role of somatostatin 
analogs for the treatment of patients with gastroenteropancreatic 
neuroendocrine tumors. Semin Oncol. 2013;40(1):56–68. https:// 
doi. org/ 10. 1053/j. semin oncol. 2012. 11. 006.
 15. Oberg KE. The management of neuroendocrine tumours: current 
and future medical therapy options. Clin Oncol (R Coll Radiol). 
2012;24(4):282–93. https:// doi. org/ 10. 1016/j. clon. 2011. 08. 006.
 16. Vinik AI, Wolin EM, Liyanage N, Gomez-Panzani E, Fisher GA, 
ELECT Study Group. Evaluation of lanreotide depot/autogel 
efficacy and safety as a carcinoid syndrome treatment (elect): a 
randomized, double-blind, placebo-controlled trial. Endocr Pract. 
2016;22(9):1068–80. https:// doi. org/ 10. 4158/ EP151 172. OR.
 17. Pearman TP, Beaumont JL, Cella D, Neary MP, Yao J. Health-
related quality of life in patients with neuroendocrine tumors: 
an investigation of treatment type, disease status, and symptom 
burden. Support Care Cancer. 2016;24(9):3695–703. https:// doi. 
org/ 10. 1007/ s00520- 016- 3189-z.
 18. Beaumont JL, Cella D, Phan AT, Choi S, Liu Z, Yao JC. Com-
parison of health-related quality of life in patients with neuroen-
docrine tumors with quality of life in the general US population. 
Pancreas. 2012;41(3):461–6. https:// doi. org/ 10. 1097/ MPA. 0b013 
e3182 328045.
 19. Fröjd C, Larsson G, Lampic C, von Essen L. Health related quality 
of life and psychosocial function among patients with carcinoid 
tumours. A longitudinal, prospective, and comparative study. 
Health Qual Life Outcomes. 2007;5:18. https:// doi. org/ 10. 1186/ 
1477- 7525-5- 18.
 20. Shen C, Chu Y, Halperin DM, et al. Carcinoid syndrome and costs 
of care during the first year after diagnosis of neuroendocrine 
tumors among elderly patients. Oncologist. 2017;22(12):1451–62. 
https:// doi. org/ 10. 1634/ theon colog ist. 2017- 0149.
 21. Broder MS, Chang E, Romanus D, Cherepanov D, Neary MP. 
Healthcare and economic impact of diarrhea in patients with car-
cinoid syndrome. World J Gastroenterol. 2016;22(6):2118–25. 
https:// doi. org/ 10. 3748/ wjg. v22. i6. 2118.
 22. Huynh L, Totev T, Vekeman F, Neary MP, Duh MS, Benson AB. 
Cost reduction from resolution/improvement of carcinoid syn-
drome symptoms following treatment with above-standard dose 
of octreotide LAR. J Med Econ. 2017;20(9):945–51. https:// doi. 
org/ 10. 1080/ 13696 998. 2017. 13370 19.
 23. Lesén E, Björstad Å, Björholt I, et al. Real-world treatment pat-
terns, resource use and costs of treating uncontrolled carcinoid 
syndrome and carcinoid heart disease: a retrospective Swedish 
study. Scand J Gastroenterol. 2018;53(12):1509–18. https:// doi. 
org/ 10. 1080/ 00365 521. 2018. 15316 53.
 24. Reilly MC, Zbrozek AS, Dukes EM. The validity and reproduc-
ibility of a work productivity and activity impairment instrument. 
Pharmacoeconomics. 1993;4(5):353–65. https:// doi. org/ 10. 2165/ 
00019 053- 19930 4050- 00006.
 25. Website: http:// www. reill yasso ciates. net/ WPAI_ Scori ng. html. 
Accessed 02 Jul 2020.
 26. ISPE. Guidelines for good pharmacoepidemiology practices 
(GPP). Pharmacoepidemiol Drug Saf. 2008;17(2):200–8. https:// 
doi. org/ 10. 1002/ pds. 1471.
 27. Website: http:// esalud. oblik ue. com/ (website in Spanish). 
Accessed 02 Jul 2020..
 28. Website: https:// botpl usweb. porta lfarma. com/ (website in Span-
ish). Accessed 02 Jul 2020
 29. Pavel ME, Hainsworth JD, Baudin E, et  al. Everolimus plus 
octreotide long-acting repeatable for the treatment of advanced 
neuroendocrine tumours associated with carcinoid syndrome 
(RADIANT-2): a randomised, placebo-controlled, phase 3 study. 
Lancet. 2011;378(9808):2005–12. https:// doi. org/ 10. 1016/ S0140- 
6736(11) 61742-X.
 30. Lesén E, Granfeldt D, Houchard A, et al. Cost-of-illness of meta-
static gastroenteropancreatic neuroendocrine tumours in Sweden-
A population-based register-linkage study. Eur J Cancer Care 
(Engl). 2019;28(2):e12983. https:// doi. org/ 10. 1111/ ecc. 12983.
 31. Haugland T, Vatn MH, Veenstra M, Wahl AK, Natvig GK. Health 
related quality of life in patients with neuroendocrine tumors com-
pared with the general Norwegian population. Qual Life Res. 
2009;18(6):719–26. https:// doi. org/ 10. 1007/ s11136- 009- 9487-x.
 32. Larrson G, Sjöden PO, Öberg K, Eriksson B, Von Essen L. 
Health-related quality of life, anxiety and depression in patients 
with midgut carcinoid tumours. Acta Oncol. 2001;40(7):825–31. 
https:// doi. org/ 10. 1080/ 02841 86015 27034 45.
Publisher’s Note Springer Nature remains neutral with regard to 
jurisdictional claims in published maps and institutional affiliations.
